Aglatimagene besadenovec - Advantagene

Drug Profile

Aglatimagene besadenovec - Advantagene

Alternative Names: Adenovirus herpes simplex virus thymidine kinase gene therapy - Advantagene; AdV-Tk; AdV-tk therapy - Advantagene; ADV/HSV-tk; CanAtak; Cancer gene therapy - Advantagene; Gene Mediated Cytotoxic Immunotherapy; GliAtak; OncAtak; PancAtak; ProstAtak; TKR therapy - Advantagene; Virafir

Latest Information Update: 01 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advantagene
  • Developer Advantagene; Baylor College of Medicine; Methodist Healthcare Ministries of South Texas
  • Class Antineoplastics; Gene therapies; Gene-directed enzyme-prodrug therapies
  • Mechanism of Action Thymidine kinase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Breast cancer; Glioma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Glioblastoma; Malignant pleural effusion; Ovarian cancer
  • Preclinical Mesothelioma; Oesophageal cancer

Most Recent Events

  • 05 Jun 2018 Methodist Healthcare Ministries of South Texas plans a phase II trial for Prostate cancer (Combination therapy, First-line therapy) in USA in July 2018 (NCT03541928)
  • 27 Apr 2018 Advantagene and Bristol-Myers Squibb enter a clinical trial collaboration for Glioblastoma (Combination therapy)
  • 28 Feb 2018 The Methodist Hospital System initiates enrolment in a phase I/II trial for Glioblastoma in USA (NCT03603405)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top